Caleres (NYSE:CAL) reported quarterly adjusted earnings of $0.65 per share which met the analyst consensus estimate. This is a 28.57 percent decrease over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $696.40 million which beat the analyst consensus estimate of $689.71 million by 0.97 percent. This is a 2.52 percent increase over sales of $679.28 million the same period last year.
UPDATE: FDA CRL To Spectrum Pharmaceuticals Cited Deficiencies Related To Manufacturing And Indicated That A Reinspection Will Be Necessary
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration
